ArticleCurrent medicinal chemistry2026
Enhanced Antioxidant and Anti-bacterial Potential of
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChitosan nanoparticles (CNPs) are broadly explored for drug delivery due to their biocompatibility, biodegradability, and non-toxicity. This study encapsulated Brugmansia suaveolens leaf ethanol extract (BSLEE) into CNPs to enhance antioxidant and antibacterial activity. MATERIALS AND
methodsThe optimization of synthesis, such as chitosan concentration of (1:1) to cross-link BSLEE, maintaining an optimal acidic pH (~4.5-5.5), and applying mild stirring at 50 rpm resulted in an encapsulation efficiency ranging from 26.33 to 48.58%, indicating the successful encapsulation of BSLEE within the CNPs. Characterization by UV-Vis, FTIR, SEM, XRD, EDX, and zeta potential confirmed successful formulation, with semi-crystalline, porous nanoparticles.
resultsDPPH, FRAP, and total phenolics assay indicate BSLEE CNPs exhibited stronger antioxidant activity in the range of 30.42 ±0.77% to 55.85± 0.69% of DPPH inhibition, 34.73±2.71 to 121.44±1.83 μg/ml FSE, and 58±2.27 to 149.5±2.48 μg GAE/ml, respectively, when compared to crude BSLEE. The antibacterial effectiveness of BSLEE CNPs against S. aureus and E. coli was more significant when compared to the BSLEE and chitosan alone, attributed to enhanced membrane permeability and disruption of the bacterial cell membrane. DISCUSSION: Antibacterial studies showed significant inhibition against S. aureus and E. coli, linked to improved membrane disruption. The BSLEE CNPs demonstrated promising biocompatibility and potential for application in antimicrobial and antioxidant therapies, warranting further clinical validation and in vitro findings of BSLEE-conjugated chitosan nanoparticles.
conclusionThe BSLEE CNPs showed promising pharmacological properties like antibacterial efficacy against E. coli and S. aureus, indicating their potential as an alternative approach to combat bacterial infections.
Indexed as
Identifiers
41572768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.